Jiangsu Sihuan Bioengineering Co., Ltd

000518.SZ - Shenzhen - Healthcare - Biotechnology

Jiangsu Sihuan Bioengineering Co., Ltd., together with its subsidiaries, engages in the production and sales of biopharmaceutical products in China and internationally. The company offers Delusen and New Delusen, a human interleukin-2 for injection are immunomodulators used for the biotherapy of tumors and treatment of patients with weakened immune function; Xinlisheng, a human granulocyte colony-stimulating factor injection used to treat neutropenia caused by bone marrow transplantation, cancer chemotherapy, myelodysplastic syndrome, and aplastic anemia; and Huanerbo, a human erythropoietin injection used to treat symptoms, such as anemia caused by renal insufficiency. It is also involved in the provision of flower planting; forest and natural ecosystem management and protection; forest improvement; forestry product sales; Chinese herbal medicine planting; landscaping project construction; urban municipal greening management; scenic area management; municipal facilities management; earthwork construction; engineering management services; forest park management and design management; external contracting; project cost consulting services; and sale of metal material, agricultural and sideline product, and building and decoration material. Jiangsu Sihuan Bioengineering Co., Ltd. was founded in 1992 and is headquartered in Jiangyin, China.

Jiangsu Sihuan Bioengineering Co., Ltd trades as 000518.SZ on Shenzhen in the Healthcare sector and Biotechnology industry. Its latest stored price is $3.14 as of June 12, 2026.

Data updated June 12, 2026

Financial Snapshot